Working Paper No. 622

Parallel Imports and the Pricing of Pharmaceutical Products: Evidence from the European Union

Publicerad: June 15, 2004Antal sidor: 36Nyckelord: Parallel Imports; International Arbitrage; Drug Pricing; Pharmaceutical Products JEL-koder: F12; I11; L12

Parallel Imports and the Pricing of Pharmaceutical Products: Evidence from the European Union Mattias Ganslandt and Keith E. Maskus


We consider policy issues regarding parallel imports (PIs) of brand-name pharmaceuticals in the European Union, where such trade is permitted. We develop a simple model in which an original manufacturer competes in its home market with PI firms. The model suggests that for small trade costs the original manufacturer will accommodate the import decisions of parallel traders and that the price in the home market falls as the volume of parallel imports rises. Using data from Sweden we find that the prices of drugs subject to competition from parallel imports fell relative to other drugs over the period 1994 - 1999. Econometric analysis finds that parallel imports significantly reduced manufacturing prices, by from 12 to 19 percent. There is evidence that this effect increases with multiple PI entrants.

 

Varför skolan slutade leverera och hur det kan åtgärdas

Kunskapssynen och pedagogiken

135087438-origpic-201a45.jpg_0_0_100_100_250_391_85.jpg

Vad är det som styr verksamheten i den svenska skolan? Förutom regelverket finns det många antaganden och föreställningar om skolan idag. Författarna menar att vi behöver frigöra oss från det rådande paradigmet och se skolsystemet från ett helt annat perspektiv. 

Institutet för Näringslivsforskning, Grevgatan 34 - 2 tr, Box 55665, SE-102 15 Stockholm, Sweden | Tel: +46-(0)8-665 45 00 | info@ifn.se